NOT FOR CLINICAL USE / SYNTHETIC DEMO — Not medical advice. Not FDA-cleared. Gate 3 is not signed. Predicted odds are from published studies only.
Workspace · Cancer algorithms · Anus
Anus · 11,270 new · 1,700 deaths (ACS 2026) · mortality 0.4 per 100k · 5-yr RS 70.9% (SEER)
Mortality 0.4 per 100k (SEER / ACS common-sites). Never an artboard percent.
Lifetime ≈ 0.2% (SEER Stat Facts). 88,564 people living with anal cancer in 2023. No encoded screening interval.
88,564 people living with this cancer in 2023 (SEER Stat Facts). Population count only — not a personal risk.
Median age at diagnosis 65 · at death 69 (SEER Stat Facts). SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Population median — not a personal risk.
Incidence men 1.6 / women 2.4 per 100k · mortality men 0.3 / women 0.4 per 100k. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. All races, age-adjusted per 100k — never an artboard percent.
Most often diagnosed among people aged 65–74. Deaths highest among people aged 65–74. SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Modal age group only — not a screening age and not a personal risk.
New cases have not changed significantly (2014–2023). Death rates rising 3.9% each year (2015–2024). Official Stat Facts Joinpoint sentence. Population trend — not a personal risk and not a screening interval.
Highest new-case rate: Non-Hispanic White women 3.1 per 100k. Highest death rate: Non-Hispanic White women 0.5 per 100k. Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.
Race/ethnicity rates per 100k (SEER Stat Facts)
| Group | Inc. men | Inc. women | Deaths men | Deaths women |
|---|---|---|---|---|
| Hispanic | 1.1 | 1.7 | 0.2 | 0.2 |
| Non-Hispanic American Indian/Alaska Native | 2.0 | 2.9 | — | — |
| Non-Hispanic Asian/Pacific Islander | 0.5 | 0.5 | 0.1 | 0.1 |
| Non-Hispanic Black | 2.5 | 1.9 | 0.4 | 0.3 |
| Non-Hispanic White | 1.7 | 3.1 | 0.3 | 0.5 |
Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.
USPSTF screening pointer
No USPSTF population-screening recommendation is cited for this stub.
ACS / SEER pin only. Not encoded. Not a screening recommendation.
ACS early-detection pointer
ACS 2025 · People considering anal-cancer early detection · ACS (2025): there is no widespread agreement on the best screening schedule, or even exactly which groups of people can benefit from screening. Digital rectal exam and anal cytology are named; neither interval is encoded. Not an anal-Pap engine.
Cited ACS statement only. Not a screening engine. ACS-anus-detect
Surveillance pointer
ACS-anus-follow 2025 · cited only · ACS after-treatment page names anoscopy and physical exams every 3 to 6 months for at least the first 3 years, with CT or MRI often done. Those months are not encoded. Not an anal-Pap engine.
Named public source only. Not a personal follow-up calendar. ACS-anus-follow
Surveillance pointer
ACS-anus-follow 2025 · cited only · ACS after-treatment page names second cancers after anal-cancer treatment, including HPV-linked tongue, tonsil, cervix, vulva, and vagina. Named later-cancer sites are not encoded. Most experts do not recommend any additional testing to look for second cancers unless you have symptoms. Complementary to the living-as pointer. Not an anal-Pap, HPV-dose, or ASCCP engine. Not a second-primary screening engine.
Named public source only. Not a personal follow-up calendar. ACS-anus-follow
Surveillance pointer
ACS-long-term-effects 2025 · cited only · ACS long-term page names bowel blockage from adhesions after pelvis treatment, plus urinary retention, leakage, or UTIs, and fertility effects after chemo or radiation to the pelvis, belly, or spine. Those names are not encoded. Complementary to the living-as pointer. Not an anal-Pap, HPV-dose, or ASCCP engine.
Named public source only. Not a personal follow-up calendar. ACS-long-term-effects
Surveillance pointer
ACS-follow-up-care 2025 · cited only · ACS follow-up-care page names a treatment summary and survivorship care plan, plus watching for recurrence and for a second cancer. Those plans are not encoded. Complementary to the GI printout. Not an anal-Pap, HPV-dose, or ASCCP engine.
Named public source only. Not a personal follow-up calendar. ACS-follow-up-care
Toxicity pointer
ACS-anus-follow 2025 · empty on purpose · ACS after-treatment page names treatment side effects that may last or appear later. Those late effects are not encoded. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-anus-follow
Toxicity pointer
ACS-anus-follow 2025 · empty on purpose · ACS after-treatment page names later cancers after anal-cancer treatment, including HPV-linked sites. Those second-cancer risks are not encoded. Complementary to the living-as pointer. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-anus-follow
Toxicity pointer
ACS-long-term-effects 2025 · empty on purpose · ACS long-term page names later bowel blockage from adhesions, urinary retention, and fertility effects after pelvis treatment. Those late effects are not encoded. Complementary to the living-as pointer. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-long-term-effects
Toxicity pointer
ACS-follow-up-care 2025 · empty on purpose · ACS follow-up-care page names a treatment summary and second-cancer watching after pelvis treatment. Those named tests are not encoded. Complementary to the GI printout. Not an anal-Pap, HPV-dose, or ASCCP engine. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-follow-up-care
Late toxicity printout
Late toxicity printout — GI
Acute: ACS names nausea, heartburn, cramps, diarrhea or constipation, bowel urgency, and rectal or anal skin irritation. Late: radiation proctitis, bowel incontinence, ostomy or chronic bowel change, neuropathy, adhesions, urinary trouble after pelvis RT, fertility effects, sexuality changes, lasting fatigue, cavities after chemo, and cognitive change after chemo. Monitor: on-treatment diarrhea; proctitis after 3 to 6 months; lasting fatigue or sleep problems; sexuality or body-image change; fertility after pelvis, belly, or spine treatment; cavity risk after chemo; memory, thinking, or focus change after chemo; a treatment summary and second-cancer watching. Those names are not encoded. Official esophagus share-of-new-cases figures are not restated. Not a Lynch or endoscopy engine.
Questions to ask
ACS long-term page lists questions to ask the care team: possible long-term and late effects, whether fertility or second-cancer risk is higher, which cancer screening tests belong later, which specialists should follow those effects, whether cancer rehabilitation could help, and when to call primary care versus cancer care. Those questions are not encoded. Not a screening, fertility, rehab, or specialist-interval engine.
ACS long-term page says not everyone who has cancer treatment gets long-term or late effects. Who does can depend on the cancer type, the type and dose of treatment, side effects during treatment, age at diagnosis, health before treatment, genetics, eating and exercise during and after treatment, care-team expertise, and support from others. Those reasons are not encoded. Not a late-effect risk-score engine.
ACS follow-up-care page lists questions to ask: how to get a treatment summary and follow-up care plan, who is in charge of follow-up, how often visits and which tests or screens belong later, signs of recurrence or a second cancer, and which survivor support services are available. Follow-up may stay with the cancer care team, move to a survivorship clinic, or return to primary care, depending on the cancer type and stage, the treatment, remaining side effects, insurance, and wishes. Those questions and choices are not encoded. Not a visit-interval, screening, or clinic-routing engine.
Treatment summary and care plan
ACS follow-up-care page names what a cancer treatment summary most often includes: diagnosis date; cancer type, including where it started, stage, and grade if known; treatments and dates, including type, dose, and number of cycles; side effects and how they were managed; test results; and names and contacts for the treating doctors. A survivorship care plan most often names remaining treatment, how often follow-up should happen, which tests including screens for other cancers, possible long-term or late effects, and ways to improve overall health. Those named contents are not encoded. Not a records, visit-interval, or screening engine.
How late effects are managed
ACS follow-up-care page says long-term side effects begin during treatment and continue after, and late side effects can start months or years later. Follow-up care may include a review of symptoms, a physical exam, blood tests to check blood counts and how the liver, kidneys, and other organs are working, and other tests as needed. Special tests after some treatments stay named on this printout. Those named steps are not encoded. Not a lab-panel, visit-interval, or screening engine.
ACS long-term late names
Named conditions to monitor
Acute toxicities · Late toxicities · Named conditions to monitor. Cadences are placeholders. Named tests are not encoded. Cited ACS abdomen / pelvis / CRC names only. Complementary ACS long-term page is named, not encoded. Official esophagus share-of-new-cases figures are not restated. No invented trial percent.
Open GI printout →NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.
algo-stub-anus · stub · none · v2-stub-anus
SEER 5-year relative survival by stage (cited stub)
Localized 85.0% · Regional 70.1% · Distant 36.5% · All 70.9%
Anus. SEER Cancer Stat Facts.
Percent of cases by stage (SEER Stat Facts)
Localized 39% · Regional 38% · Distant 14% · Unknown 8%
Percent of cases at diagnosis — not 5-year relative survival. SEER Combined Summary Stage.
lifetime
Anus birth-to-death
≈ 0.2%
Screening · Surveillance · Toxicity on four golden fixtures
Rio · Plan — survivor
not computed — v2 stubCited ACS/SEER population pin only
screening
ACS — no agreed anal-cancer screening schedule
Cited ACS 2025 statement only. Not an anal-Pap engine.
not encoded
surveillance
ACS follow-up cited — anus months not encoded
Cited ACS after-treatment page only. Not an anal-Pap engine.
not encoded
toxicity
ACS late effects cited — anus months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded
Noah · Plan — skin cancer
not computed — v2 stubCited ACS/SEER population pin only
screening
ACS — no agreed anal-cancer screening schedule
Cited ACS 2025 statement only. Not an anal-Pap engine.
not encoded
surveillance
ACS follow-up cited — anus months not encoded
Cited ACS after-treatment page only. Not an anal-Pap engine.
not encoded
toxicity
ACS late effects cited — anus months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded
Walter · S1 prostate
not computed — v2 stubCited ACS/SEER population pin only
screening
ACS — no agreed anal-cancer screening schedule
Cited ACS 2025 statement only. Not an anal-Pap engine.
not encoded
surveillance
ACS follow-up cited — anus months not encoded
Cited ACS after-treatment page only. Not an anal-Pap engine.
not encoded
toxicity
ACS late effects cited — anus months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded
Priya · average-risk
not computed — v2 stubCited ACS/SEER population pin only
screening
ACS — no agreed anal-cancer screening schedule
Cited ACS 2025 statement only. Not an anal-Pap engine.
not encoded
surveillance
ACS follow-up cited — anus months not encoded
Cited ACS after-treatment page only. Not an anal-Pap engine.
not encoded
toxicity
ACS late effects cited — anus months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded
Not implemented. Cited public snapshot only. Not a screening recommendation. Mortality is a rate per 100k, not an artboard percent.